About: Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Creator	Shi, Wei Xia, Linghui Yu, Hu Jin, Weiwei
Source	Elsevier; Medline; PMC
abstract	Relapse remains the worst life-threatening complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML), whose prognosis has been historically dismal. Given the rapid development of genomics and immunotherapies, the interference strategies for AML recurrence have been changing these years. More and more novel targeting agents that have received the U.S. Food and Drug Administration (FDA) approval for de novo AML treatment have been administrated in the salvage or maintenance therapy of post-HSCT relapse. Targeted strategies that regulate the immune microenvironment of and optimize the graft versus leukemia (GVL) effect of immune cells are gradually improved. Such agents not only have been proven to achieve clinical benefits from a single drug, but if combined with classic therapies, can significantly improve the poor prognosis of AML patients who relapse after allo-HSCT. This review will focus on currently available and promising upcoming agents and also discuss the challenges and limitations of targeted therapies in the allogeneic hematopoietic stem cell transplantation community.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1016/j.apsb.2020.06.012
bibo:pmid	32837873
has license	no-cc
sha1sum (hex)	2963c475a284a21bcfb13f88f210cf3c097e2819
schema:url	https://doi.org/10.1016/j.apsb.2020.06.012
resource representing a document's title	Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
has PubMed Central identifier	PMC7326461
has PubMed identifier	32837873
schema:publication	Acta Pharm Sin B
resource representing a document's body	covid:2963c475a284a21bcfb13f88f210cf3c097e2819#body_text
is schema:about of	named entity 'microenvironment' named entity 'allogeneic hematopoietic stem cell transplantation' named entity 'stem cells' named entity 'venetoclax' named entity 'degranulate' named entity 'immunophenotype' named entity 'cellular therapies' named entity 'ligand' named entity 'HSCT' named entity 'microenvironment' named entity 'clinical trial' named entity 'midostaurin' named entity 'RIC' named entity 'preventive treatment' named entity 'AML' named entity 'anemia' named entity 'microenvironment' named entity 'monotherapy' named entity 'WT1' named entity 'mortality rates' named entity 'HDACi' named entity 'AML' named entity 'tumor' named entity 'P<0.05' named entity 'monotherapy' named entity 'AML' named entity 'antigens' named entity 'phase 1' named entity 'HSCT' named entity 'isocitrate dehydrogenase' named entity 'epigenetic' named entity 'HSCT' named entity 'adverse events' named entity 'toxicity' named entity 'leukemia cells' named entity 'tricarboxylic acid cycle' named entity 'enasidenib' named entity 'phase 1 clinical trial' named entity 'HSCT' named entity 'CD8 +' named entity 'cytotoxic agents' named entity 'venetoclax' named entity 'isocitrate' named entity 'KIR' named entity 'leukemia' named entity 'leukemia' named entity 'histone deacetylases' named entity 'retrospective study' named entity 'control group' named entity 'CD8 +' named entity 'AML' named entity 'adverse events' named entity 'folate receptor' named entity 'antibody' named entity 'long-term' named entity 'FLT3 inhibitor' named entity 'immunotherapy' named entity 'sorafenib' named entity 'phase 3 trial' named entity 'clinical trial' named entity 'FLT3' named entity 'Myeloid' named entity 'HSCT' named entity 'phase 2' named entity 'oncogenic' named entity 'midostaurin' named entity 'PRMT5' named entity 'CD200R' named entity 'IL-2' named entity 'HSCT' named entity 'chemotherapy' named entity 'refractory' named entity 'preventive therapy' named entity 'WT1' named entity 'DLI' named entity 'GVHD' named entity 'apoptosis' named entity 'CXCL12'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software